Cocrystalline DHEA Formulations

Research output: Patent

Anders L. Berkenstam (Inventor), Edward Kuczynski, (Inventor), S Andersson, Alf (Inventor), Jan-Ake Gustafsson (Inventor), Carly S. Filgueira (Inventor)

A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

Original languageEnglish (US)
Patent numberUS2014315833
IPCC07C 49/ 727 A I
Priority date4/21/14
StatePublished - Oct 23 2014

Cite this

Standard

Cocrystalline DHEA Formulations. / Berkenstam, Anders L. (Inventor); Kuczynski, Edward (Inventor); Andersson, Alf, S (Inventor); Gustafsson, Jan-Ake (Inventor); Filgueira, Carly S. (Inventor).

IPC No.: C07C 49/ 727 A I. Patent No.: US2014315833.

Research output: Patent

Harvard

Berkenstam, AL, Kuczynski, E, Andersson, Alf, S, Gustafsson, J-A & Filgueira, CS 2014, Cocrystalline DHEA Formulations, Patent No. US2014315833, IPC No. C07C 49/ 727 A I.

APA

Berkenstam, A. L., Kuczynski, E., Andersson, Alf, S., Gustafsson, J-A., & Filgueira, C. S. (2014). IPC No. C07C 49/ 727 A I. Cocrystalline DHEA Formulations. (Patent No. US2014315833).

Vancouver

Berkenstam AL, Kuczynski, E, Andersson, Alf S, Gustafsson J-A, Filgueira CS, inventors. Cocrystalline DHEA Formulations. C07C 49/ 727 A I. 2014 Oct 23.

Author

Berkenstam, Anders L. (Inventor) ; Kuczynski, Edward (Inventor) ; Andersson, Alf, S (Inventor) ; Gustafsson, Jan-Ake (Inventor) ; Filgueira, Carly S. (Inventor). / Cocrystalline DHEA Formulations. IPC No.: C07C 49/ 727 A I. Patent No.: US2014315833.

BibTeX

@misc{4b9a8cb3c4834b919180f54b6dd59b0f,
title = "Cocrystalline DHEA Formulations",
abstract = "A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.",
author = "Berkenstam, {Anders L.} and Edward Kuczynski, and {Andersson, Alf}, S and Jan-Ake Gustafsson and Filgueira, {Carly S.}",
year = "2014",
month = "10",
day = "23",
language = "English (US)",
type = "Patent",
note = "US2014315833; C07C 49/ 727 A I",

}

RIS

TY - PAT

T1 - Cocrystalline DHEA Formulations

AU - Berkenstam, Anders L.

AU - Kuczynski,, Edward

AU - Andersson, Alf, S

AU - Gustafsson, Jan-Ake

AU - Filgueira, Carly S.

PY - 2014/10/23

Y1 - 2014/10/23

N2 - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

AB - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

M3 - Patent

M1 - US2014315833

ER -

Similar Research Outputs

  1. COCRYSTALLINE DHEA FORMULATIONS

    Berkenstam, A. L., Kuczynski, E., Andersson, Alf, S., Gustafsson, J-A. & Filgueira, C. S., Oct 23 2014, IPC No. A61K 38/ 22 A I, Patent No. WO2014172706, Priority date Apr 19 2013, Priority No. US201361813920P

    Research output: Patent

ID: 32366097